Cardurion Pharmaceuticals
BURLINGTON, MA · Founded 2017 · CIK 0001702453 · Biotech · Private
Small molecule therapeutics for cardiovascular disease and heart failure
cardurion.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $350M
- 5 Form D · Jul 2024
- 27 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 36
- 11 granted · 25 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $15,650,000 | |
| Private capital raised | Form D · SEC | $10,000,000 | |
| Private capital raised | Form D · SEC | $46,125,000 | |
| Private capital raised | Form D · SEC | $17,500,000 | |
| Private capital raised | Form D · SEC | $260,410,720 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2844 | GRADIENT BIOMODELING, LLC | — | — |
| 2845 | Solid Biosciences | — | $109M |
| 2846 | Lomond Therapeutics | — | — |
| 2847 | Cardurion Pharmaceuticals | — | $350M |
| 2848 | DIGITAL NANOGENETICS, LLC | — | — |
| 2849 | RETINAL SOLUTIONS LLC | — | — |
| 2850 | Stipple Bio | — | $87M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Nicholas DowningDirector
- Keith GottesdienerDirector
- Jeb KeiperDirector
- Adam KoppelDirector
- Peter LawrenceDirector · Executive Officer
- Daniel LynchDirector
- Edward MathersDirector
- Michael MendelsohnDirector · Executive Officer
- Kenneth NovackDirector
- Evan RachlinDirector
- Emma ReeveDirector
- Amy SchulmanDirector
Patents
- Monohydrate And Crystalline Forms Of 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO [1,5- A] PYRAZIN-8-ONEapplication
- PROCESS FOR THE SYNTHESIS OF 6-((3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-3-(TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-a]PYRAZIN-8-ONEapplication
- SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORSgranted
- Monohydrate And Crystalline Forms Of 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONEgranted
- Polymorphs Of A PYRIDINYLIMIDAZO[1,2-B]PYRIDAZINEapplication
- PDE9 Inhibitors For Treating Sickle Cell Diseaseapplication
- PDE9 Inhibitors For Treating Sickle Cell Diseasegranted
- PROCESS FOR THE SYNTHESIS OF 6-((3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-3-(TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-a]PYRAZIN-8-ONEapplication
- Monohydrate And Crystalline Forms Of 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONEgranted
- PROCESS FOR THE SYNTHESIS OF 6-((3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-3-(TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-a]PYRAZIN-8-ONEgranted
- SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES AND [1,2,4]TRIAZOLO[4,3-b]PYRIDAZINES AS CAMKII INHIBITORSgranted
- Aminopyrimidine Compoundapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.